GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended September 30, 2022
9% Sales growth across General Medicines and Specialty business
GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the quarter ended September 30, 2022. Revenue (from continuing operations) for the quarter came in at Rs 906 crores. PAT for the period (from continuing operations) at Rs 194 crores recorded a growth of 3%. EBITDA margins (from continuing operations) improving by 63 basis point.
Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “GSK India has delivered another quarter of strong performance in general medicines and specialty business, gaining market share. We hope to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth.
Vaccines business was impacted due to low vaccination rates, as the overall market for the self-pay segment in which we operate continues to decline. We maintain market leadership in the private vaccines market as many of our key brands gained share, fuelled by disciplined execution.”
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together. For more information, visit GSK-India.com
Communications & Government Affairs